PD-L1 Inhibitor Improves Survival in TNBC
- PMID: 30464002
- DOI: 10.1158/2159-8290.CD-NB2018-154
PD-L1 Inhibitor Improves Survival in TNBC
Abstract
Combining the PD-L1 inhibitor atezolizumab with standard chemotherapy improves overall survival among patients with metastatic triple-negative breast cancer relative to chemotherapy alone. These findings could lead to a new treatment option for patients with this disease.
©2018 American Association for Cancer Research.
Comment on
-
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.N Engl J Med. 2018 Nov 29;379(22):2108-2121. doi: 10.1056/NEJMoa1809615. Epub 2018 Oct 20. N Engl J Med. 2018. PMID: 30345906 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
